7-氨基二环<2.2.1>庚烷 | 35092-58-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 7-氨基二环<2.2.1>庚烷
• 中文别名: 双环[2.2.1]庚-7-胺
• 英文名称: 7-Aminobicyclo<2.2.1>heptane
• 英文别名: 7-Amino-norbornan；7-Aminonorbornan；Bicyclo[2.2.1]heptan-7-amine
• CAS: 35092-58-1
• 化学式: C₇H₁₃N
• mdl: MFCD19216699
• 分子量: 111.187
• InChiKey: FFEOZXJNAVXZRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-氨基二环<2.2.1>庚烷 在 吡啶 作用下， 以 乙醇 、 苯 为溶剂， 生成 7-Diaethylaminoacetamino-norbornan
  参考文献：
  名称：

  Structure--Activity Relationships in a Series of Antiarrhythmic and Local Anaesthetic Bicyclic Glycinamides

  摘要：

  DOI：

  10.1021/jm50017a014
• 作为产物：
  描述：

  双环[2.2.1]庚烷-7-羧酸 在 叠氮磷酸二苯酯 、 三乙胺 、 三氟乙酸 作用下， 以 乙腈 、 叔丁醇 、 二氯甲烷 、 氯仿 为溶剂， 生成 7-氨基二环<2.2.1>庚烷
  参考文献：
  名称：

  2-Amino-1,3-thiazol-4(5H)-ones as Potent and Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Enzyme−Ligand Co-Crystal Structure and Demonstration of Pharmacodynamic Effects in C57Bl/6 Mice

  摘要：

  11 beta-Hydroxy steroid dehydrogenase type 1 (11 beta-HSD1) has attracted considerable attention during the past few years as a potential target for the treatment of diseases associated with metabolic syndrome. In our ongoing work on 11-HSD1 inhibitors, a series of new 2-amino-1,3-thiazol-4(5H)-ones were explored. By inserting various cycloalkylamines at the 2-position and alkyl groups or spirocycloalkyl groups at the 5-position of the thiazolone, several potent 11 beta-HSD1 inhibitors were identified. An X-ray cocrystal structure of human 11 beta-HSD1 with compound 6d (K-i = 28 nM) revealed a large lipophilic pocket accessible by substitution off the 2-position of the thiazolone. To increase potency, analogues were prepared with larger lipophilic groups at this position. One of these compounds, the 3-noradamantyl analogue 8b, was a potent inhibitor of human 11 beta-HSD 1 (K-i = 3 nM) and also inhibited 11 beta-HSD1 activity in lean C57BI/6 mice when evaluated in an ex vivo adipose and liver cortisone to cortisol conversion assay.

  DOI：

  10.1021/jm701551j

文献信息

• Synthesis and Pharmacological Evaluation of 4-Iminothiazolidinones for Inhibition of PI3 Kinase
  作者：Jo-Anne Pinson、Oleg Schmidt-Kittler、Mark Frazzetto、Zhaohua Zheng、Ian G. Jennings、Kenneth W. Kinzler、Bert Vogelstein、David K. Chalmers、Philip E. Thompson

  DOI：10.1071/ch12140

  日期：——

  The thiazolidinedione, compound 1, has previously shown pan-inhibition of the phosphoinositide 3-kinase (PI3K) class I isoforms. We hypothesized the derivatization of the thiazolidinedione core of compound 1 could introduce isoform selectivity. We report the synthesis, characterization, and inhibitory activity of a novel series of 4-iminothiazolidin-2-ones for inhibition of the class I PI3K isoforms. Their synthesis was successfully achieved by multiple pathways described in this paper. Initial in vitro data of 28 analogues demonstrated poor inhibition of all class I PI3K isoforms. However, we identified an alternate target, the phosphodiesterases, and present preliminary screening results showing improved inhibitory activity.

  噻唑烷二酮化合物 1 以前曾显示出对磷酸肌酸 3-激酶（PI3K）I 类同工酶的泛抑制作用。我们假设化合物 1 的噻唑烷二酮核心的衍生化可以带来同工酶的选择性。我们报告了一系列新型 4-亚氨基噻唑烷-2-酮的合成、表征和抑制 I 类 PI3K 同工酶的活性。本文描述的多种途径成功实现了这些化合物的合成。28 种类似物的初步体外数据显示，它们对所有 I 类 PI3K 同工酶的抑制效果都很差。不过，我们发现了另一个靶点--磷酸二酯酶，并提出了初步筛选结果，显示其抑制活性有所提高。
• METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND
  申请人：Komiyama Masato

  公开号：US20130158272A1

  公开（公告）日：2013-06-20

  The present invention provides a method for producing a xanthine oxidase inhibitor, which is a therapeutic agent for hyperuricemia, or intermediates of the same, said method being efficient and using a short process. The present invention is a novel coupling method for obtaining a compound represented by formula (3) by bringing about a coupling reaction between a compound represented by formula (1) and a compound represented by formula (2), in the presence of a palladium compound, a ligand capable of coordinating to the palladium compound, a base, a C 1 -C 40 carboxylic acid, and at least one kind of additive.

  本发明提供了一种生产黄嘌呤氧化酶抑制剂的方法，该抑制剂是治疗高尿酸血症的药物，或者其中间体，该方法高效且使用流程简短。本发明是一种新型耦合方法，通过在钯化合物、能够配位到钯化合物的配体、碱、C1-C40羧酸和至少一种添加剂的存在下，在式（1）所代表的化合物和式（2）所代表的化合物之间引发耦合反应，从而获得式（3）所代表的化合物。
• A Convenient Synthesis of 7-Nitrobicyclo[2.2.1]heptane from Bicyclo[2.2.1]hept-2-ene<i>via</i>7-Aminobicyclo[2.2.1]heptane
  作者：Kimitoshi Fukunaga、Christoph Rüchardt

  DOI：10.1055/s-1987-28181

  日期：——

  syn-7-(Methoxycarbonylamino)bicyclo[2.2.1]hept-2-ene (5), prepared from bicyclo[2.2.1]hept-2-ene (1) in 52% overall yield according to literature procedures, was hydrogenated over palladized charcoal to yield 7-(methoxycarbonylamino)bicyclo[2.2.1]heptane (6). Alkaline hydrolysis of 6 gave 7-aminobicyclo[2.2.1]heptane (7), which was readily oxidized with m-chloroperoxybenzoic acid in boiling dichloroethane to 7-nitrobicyclo[2.2.1]heptane (8). The reported synthesis constitutes an efficient entry into the 7-substituted bicyclo[2.2.1]heptane series and allows for the preparation of the previously unknown nitro-derivative 8 in 23% overall yield from 1.

  合成-7-(甲氧基羰基氨基)双环[2.2.1]庚-2-烯 (5)是根据文献中的方法从双环[2.2.1]庚-2-烯 (1) 制备的，总收率为 52%，在苍白木炭上氢化后得到 7-(甲氧基羰基氨基)双环[2.2.1]庚烷 (6)。碱性水解 6 得到 7-氨基双环[2.2.1]庚烷（7），在沸腾的二氯乙烷中用间氯过氧苯甲酸很容易将其氧化为 7-硝基双环[2.2.1]庚烷（8）。所报道的合成方法是进入 7-取代双环[2.2.1]庚烷系列的有效途径，并能以 23% 的总收率从 1 制备出之前未知的硝基衍生物 8。
• Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
  申请人：PLETTENBURG Oliver

  公开号：US20100056553A1

  公开（公告）日：2010-03-04

  The invention relates to 6-substituted isoquinoline and isoquinolinone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

  本发明涉及公式（I）的6-取代的异喹啉和异喹啉酮衍生物，可用于治疗和/或预防与Rho-激酶和/或Rho-激酶介导的肌球蛋白轻链磷酸酶的磷酸化相关的疾病，以及含有这些化合物的组合物。
• Bicyclo[2.2.1]hept-7-ylamine Derivatives and Their Uses
  申请人：Finch Harry

  公开号：US20100144852A1

  公开（公告）日：2010-06-10

  Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula (I) wherein A is an oxygen atom or group —N(R 12 )—; (i) R 1 is C 1 -C 6 -alkyl or a hydrogen atom; and R 2 is a hydrogen atom or a group —R 5 , —Z—Y—R 5 —Z—NR 9 R 10 ; —Z—CO—NR 9 R 10 ; —Z—NR 9 —CO—R 5 ; or —Z—CO 2 H; and R 3 is a lone pair, or C 1 -C 6 -alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R 1 and R 3 together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R 2 is a hydrogen atom; or a group —R 5 , —Z—Y—R 5 , —Z—NR 9 R 10 , —Z—CO—NR 9 R 10 , —Z—NR 9 —CO—R 5 , or —Z—CO 2 H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R 1 and R 2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R 5 , —Z—Y—R 5 , —Z—NR 9 R 10 ; —Z—CO—NR 9 R 10 ; —Z—NR 9 —CO—R 5 ; or —Z—CO 2 H and R 3 is a lone pair, or C 1 -C 6 -alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; R 4 is a group of formula (a), (b), (c) or (d); is an C 1 -C 6 -alkyl, aryl, aryl-fused-cycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl, aryl(C 1 -C 8 -alkyl)-, heteroaryl(C 1 -C 8 -alkyl)-, cycloalkyl or heterocycloalkyl group, and the remaining variables are as defined in the specification.

  式(I)的化合物具有肌动蛋白M3受体调节活性；其中A是氧原子或基团-N(R12)-; (i) R1是C1-C6-烷基或氢原子；R2是氢原子或基团-R5、-Z-Y-R5-Z-NR9R10、-Z-CO-NR9R10、-Z-NR9-CO-R5或-Z-CO2H；R3是孤对电子，或C1-C6-烷基，此时它连接的氮原子是季铵氮并带有正电荷；或者(ii) R1和R3与它们连接的氮形成杂环烷基环，R2是氢原子；或者是一个基团-R5、-Z-Y-R5、-Z-NR9R10、-Z-CO-NR9R10、-Z-NR9-CO-R5或-Z-CO2H，此时连接它的氮原子是季铵氮并带有正电荷；或者(iii) R1和R2与它们连接的氮形成杂环烷基环，所述环被基团-Y-R5、-Z-Y-R5、-Z-NR9R10、-Z-CO-NR9R10、-Z-NR9-CO-R5或-Z-CO2H取代，R3是孤对电子，或C1-C6-烷基，此时连接它的氮原子是季铵氮并带有正电荷；R4是式(a)、(b)、(c)或(d)的基团；是C1-C6-烷基、芳基、芳基融合环烷基、芳基融合杂环烷基、杂环芳基、芳基(C1-C8-烷基)-、杂环芳基(C1-C8-烷基)-、环烷基或杂环烷基基团，其余变量如说明书所定义。